Precision Reimbursement strategies hold promise for lowering cost and improving patient access to treatment options across a spectrum of disease areas. Through incentive alignment for all stakeholders, we have the opportunity to realize success in lowering costs and improving access through innovative outcomes contracting tools.

While great strides have been made in addressing cardiovascular disease by managing risk factors, opportunities to improve patient outcomes exist for all stakeholders. High LDL cholesterol is a key modifiable risk factor for cardiovascular disease. Despite the availability of effective lipid lowering therapies, initiation and adherence to statins and newer therapeutic agents is low. Too few ASCVD and other high-risk patients are achieving LDL targets and remaining on therapy for the length of time needed to adequately manage their disease progression and reduce cardiovascular events.

Effective lipid management can continue to create significant improvements in mortality and morbidity for ASCVD and other high-risk patients, but we need to address two challenges simultaneously:

• Identifying and minimizing the continuing lipid management clinical gaps
• Recognizing and addressing the incentive gaps for stakeholder action, including those that can be addressed through Precision Reimbursement designs

Making substantial progress on these challenges needs coordinated action from all stakeholders – patients, providers, health systems, payers, and policy makers. How can we leverage Precision Reimbursement tools to address these incentive issues and facilitate timely and effective lipid management? How can we demonstrate and realize the value of better lipid management for cardiovascular disease outcomes?